nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—hematologic cancer—muscle cancer	0.486	1	CtDrD
Nilotinib—KIT—muscle cancer	0.24	1	CbGaD
Nilotinib—UGT1A1—Etoposide—muscle cancer	0.0187	0.169	CbGbCtD
Nilotinib—ABCG2—Dactinomycin—muscle cancer	0.0183	0.165	CbGbCtD
Nilotinib—ABCG2—Vincristine—muscle cancer	0.0112	0.102	CbGbCtD
Nilotinib—ABCG2—Etoposide—muscle cancer	0.0103	0.0931	CbGbCtD
Nilotinib—ABCG2—Doxorubicin—muscle cancer	0.00703	0.0635	CbGbCtD
Nilotinib—ABCG2—Methotrexate—muscle cancer	0.00681	0.0615	CbGbCtD
Nilotinib—ABCB1—Dactinomycin—muscle cancer	0.00658	0.0595	CbGbCtD
Nilotinib—CYP2C8—Etoposide—muscle cancer	0.00549	0.0496	CbGbCtD
Nilotinib—CYP2B6—Doxorubicin—muscle cancer	0.00494	0.0446	CbGbCtD
Nilotinib—ABCB1—Vincristine—muscle cancer	0.00405	0.0366	CbGbCtD
Nilotinib—ABCB1—Etoposide—muscle cancer	0.00371	0.0336	CbGbCtD
Nilotinib—ABCB1—Doxorubicin—muscle cancer	0.00253	0.0229	CbGbCtD
Nilotinib—ABCB1—Methotrexate—muscle cancer	0.00245	0.0222	CbGbCtD
Nilotinib—CYP3A4—Vincristine—muscle cancer	0.00243	0.0219	CbGbCtD
Nilotinib—CYP2D6—Doxorubicin—muscle cancer	0.00239	0.0216	CbGbCtD
Nilotinib—CYP3A4—Etoposide—muscle cancer	0.00223	0.0201	CbGbCtD
Nilotinib—CYP3A4—Doxorubicin—muscle cancer	0.00152	0.0137	CbGbCtD
Nilotinib—Ponatinib—KIT—muscle cancer	0.00147	0.619	CrCbGaD
Nilotinib—Imatinib—KIT—muscle cancer	0.000903	0.381	CrCbGaD
Nilotinib—MAPK8—embryo—muscle cancer	0.000639	0.0143	CbGeAlD
Nilotinib—FRK—renal system—muscle cancer	0.000634	0.0141	CbGeAlD
Nilotinib—CDC42BPB—smooth muscle tissue—muscle cancer	0.000556	0.0124	CbGeAlD
Nilotinib—CDC42BPB—renal system—muscle cancer	0.000535	0.0119	CbGeAlD
Nilotinib—EPHB3—embryo—muscle cancer	0.000527	0.0118	CbGeAlD
Nilotinib—MAPK8—smooth muscle tissue—muscle cancer	0.000503	0.0112	CbGeAlD
Nilotinib—MAPK8—renal system—muscle cancer	0.000484	0.0108	CbGeAlD
Nilotinib—CDC42BPB—cardiac atrium—muscle cancer	0.000479	0.0107	CbGeAlD
Nilotinib—EPHA4—embryo—muscle cancer	0.00044	0.00982	CbGeAlD
Nilotinib—TIE1—smooth muscle tissue—muscle cancer	0.000436	0.00972	CbGeAlD
Nilotinib—CDC42BPB—tendon—muscle cancer	0.000418	0.00931	CbGeAlD
Nilotinib—FRK—testis—muscle cancer	0.00041	0.00914	CbGeAlD
Nilotinib—MAPK14—embryo—muscle cancer	0.000406	0.00905	CbGeAlD
Nilotinib—EPHB2—head—muscle cancer	0.000405	0.00903	CbGeAlD
Nilotinib—FGR—embryo—muscle cancer	0.000404	0.00902	CbGeAlD
Nilotinib—EPHA8—head—muscle cancer	0.000388	0.00866	CbGeAlD
Nilotinib—CDC42BPB—vagina—muscle cancer	0.000388	0.00864	CbGeAlD
Nilotinib—MAPK8—tendon—muscle cancer	0.000378	0.00842	CbGeAlD
Nilotinib—TIE1—cardiac atrium—muscle cancer	0.000376	0.00838	CbGeAlD
Nilotinib—EPHA8—testis—muscle cancer	0.000375	0.00836	CbGeAlD
Nilotinib—TEK—embryo—muscle cancer	0.000368	0.00821	CbGeAlD
Nilotinib—MAPK8—bone marrow—muscle cancer	0.000366	0.00816	CbGeAlD
Nilotinib—MAPK11—head—muscle cancer	0.000361	0.00805	CbGeAlD
Nilotinib—CA7—renal system—muscle cancer	0.000359	0.008	CbGeAlD
Nilotinib—CDC42BPB—head—muscle cancer	0.000358	0.00798	CbGeAlD
Nilotinib—MAPK8—vagina—muscle cancer	0.00035	0.00781	CbGeAlD
Nilotinib—MAPK11—testis—muscle cancer	0.000349	0.00777	CbGeAlD
Nilotinib—ABL1—Idarubicin—Doxorubicin—muscle cancer	0.000347	0.333	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Doxorubicin—muscle cancer	0.000347	0.333	CbGdCrCtD
Nilotinib—ABL1—Epirubicin—Doxorubicin—muscle cancer	0.000347	0.333	CbGdCrCtD
Nilotinib—CDC42BPB—testis—muscle cancer	0.000346	0.00771	CbGeAlD
Nilotinib—MAP4K1—tendon—muscle cancer	0.000343	0.00765	CbGeAlD
Nilotinib—EPHA3—head—muscle cancer	0.000339	0.00757	CbGeAlD
Nilotinib—PDGFRA—embryo—muscle cancer	0.000334	0.00744	CbGeAlD
Nilotinib—MAP4K1—bone marrow—muscle cancer	0.000332	0.00741	CbGeAlD
Nilotinib—EPHA3—testis—muscle cancer	0.000328	0.00731	CbGeAlD
Nilotinib—MAPK8—head—muscle cancer	0.000324	0.00722	CbGeAlD
Nilotinib—EPHA6—head—muscle cancer	0.000324	0.00722	CbGeAlD
Nilotinib—MAPK14—smooth muscle tissue—muscle cancer	0.000319	0.00712	CbGeAlD
Nilotinib—MAP4K1—vagina—muscle cancer	0.000319	0.0071	CbGeAlD
Nilotinib—BRAF—tendon—muscle cancer	0.000314	0.007	CbGeAlD
Nilotinib—MAPK8—testis—muscle cancer	0.000313	0.00697	CbGeAlD
Nilotinib—EPHA6—testis—muscle cancer	0.000313	0.00697	CbGeAlD
Nilotinib—MAPK14—renal system—muscle cancer	0.000307	0.00685	CbGeAlD
Nilotinib—BRAF—bone marrow—muscle cancer	0.000304	0.00678	CbGeAlD
Nilotinib—EPHB4—smooth muscle tissue—muscle cancer	0.000303	0.00675	CbGeAlD
Nilotinib—LYN—head—muscle cancer	0.000299	0.00666	CbGeAlD
Nilotinib—EPHA4—cardiac atrium—muscle cancer	0.000298	0.00665	CbGeAlD
Nilotinib—CA3—cardiac atrium—muscle cancer	0.000295	0.00657	CbGeAlD
Nilotinib—CSF1R—embryo—muscle cancer	0.000294	0.00655	CbGeAlD
Nilotinib—BRAF—vagina—muscle cancer	0.000291	0.0065	CbGeAlD
Nilotinib—EPHB4—renal system—muscle cancer	0.000291	0.0065	CbGeAlD
Nilotinib—TEK—smooth muscle tissue—muscle cancer	0.00029	0.00646	CbGeAlD
Nilotinib—EPHB3—vagina—muscle cancer	0.000289	0.00644	CbGeAlD
Nilotinib—HCK—tendon—muscle cancer	0.000286	0.00638	CbGeAlD
Nilotinib—ABL2—tendon—muscle cancer	0.000284	0.00634	CbGeAlD
Nilotinib—MAP4K1—testis—muscle cancer	0.000284	0.00634	CbGeAlD
Nilotinib—TIE1—head—muscle cancer	0.000281	0.00626	CbGeAlD
Nilotinib—TEK—renal system—muscle cancer	0.000279	0.00622	CbGeAlD
Nilotinib—HCK—bone marrow—muscle cancer	0.000277	0.00618	CbGeAlD
Nilotinib—TIE1—testis—muscle cancer	0.000271	0.00605	CbGeAlD
Nilotinib—CA14—cardiac atrium—muscle cancer	0.000268	0.00597	CbGeAlD
Nilotinib—EPHB3—head—muscle cancer	0.000267	0.00595	CbGeAlD
Nilotinib—KIT—embryo—muscle cancer	0.000267	0.00595	CbGeAlD
Nilotinib—HCK—vagina—muscle cancer	0.000266	0.00592	CbGeAlD
Nilotinib—ABL2—vagina—muscle cancer	0.000264	0.00588	CbGeAlD
Nilotinib—PDGFRA—smooth muscle tissue—muscle cancer	0.000262	0.00585	CbGeAlD
Nilotinib—EPHB4—cardiac atrium—muscle cancer	0.000261	0.00582	CbGeAlD
Nilotinib—PDGFRB—embryo—muscle cancer	0.000261	0.00581	CbGeAlD
Nilotinib—EPHA4—tendon—muscle cancer	0.00026	0.0058	CbGeAlD
Nilotinib—BRAF—testis—muscle cancer	0.00026	0.0058	CbGeAlD
Nilotinib—EPHB3—testis—muscle cancer	0.000258	0.00575	CbGeAlD
Nilotinib—CA3—tendon—muscle cancer	0.000257	0.00573	CbGeAlD
Nilotinib—EPHA2—cardiac atrium—muscle cancer	0.000256	0.00571	CbGeAlD
Nilotinib—PDGFRA—renal system—muscle cancer	0.000253	0.00563	CbGeAlD
Nilotinib—TEK—cardiac atrium—muscle cancer	0.00025	0.00557	CbGeAlD
Nilotinib—CA3—bone marrow—muscle cancer	0.000249	0.00555	CbGeAlD
Nilotinib—CA9—tendon—muscle cancer	0.000246	0.00549	CbGeAlD
Nilotinib—HCK—head—muscle cancer	0.000245	0.00547	CbGeAlD
Nilotinib—EPHA4—vagina—muscle cancer	0.000241	0.00538	CbGeAlD
Nilotinib—UGT1A1—renal system—muscle cancer	0.000241	0.00537	CbGeAlD
Nilotinib—MAPK14—tendon—muscle cancer	0.00024	0.00535	CbGeAlD
Nilotinib—FGR—tendon—muscle cancer	0.000239	0.00533	CbGeAlD
Nilotinib—EPHB6—cardiac atrium—muscle cancer	0.000239	0.00532	CbGeAlD
Nilotinib—CA3—vagina—muscle cancer	0.000238	0.00532	CbGeAlD
Nilotinib—HCK—testis—muscle cancer	0.000237	0.00528	CbGeAlD
Nilotinib—ABL2—testis—muscle cancer	0.000236	0.00525	CbGeAlD
Nilotinib—CA14—tendon—muscle cancer	0.000233	0.0052	CbGeAlD
Nilotinib—CA12—renal system—muscle cancer	0.000233	0.0052	CbGeAlD
Nilotinib—CA6—head—muscle cancer	0.000233	0.00519	CbGeAlD
Nilotinib—MAPK14—bone marrow—muscle cancer	0.000232	0.00518	CbGeAlD
Nilotinib—ABL1—embryo—muscle cancer	0.000232	0.00518	CbGeAlD
Nilotinib—FGR—bone marrow—muscle cancer	0.000231	0.00516	CbGeAlD
Nilotinib—LCK—bone marrow—muscle cancer	0.000231	0.00516	CbGeAlD
Nilotinib—CSF1R—smooth muscle tissue—muscle cancer	0.000231	0.00515	CbGeAlD
Nilotinib—EPHB4—tendon—muscle cancer	0.000227	0.00507	CbGeAlD
Nilotinib—EPHA2—tendon—muscle cancer	0.000223	0.00497	CbGeAlD
Nilotinib—EPHA4—head—muscle cancer	0.000223	0.00497	CbGeAlD
Nilotinib—MAPK14—vagina—muscle cancer	0.000223	0.00496	CbGeAlD
Nilotinib—LCK—vagina—muscle cancer	0.000222	0.00494	CbGeAlD
Nilotinib—FGR—vagina—muscle cancer	0.000222	0.00494	CbGeAlD
Nilotinib—CA3—head—muscle cancer	0.00022	0.00491	CbGeAlD
Nilotinib—EPHB4—bone marrow—muscle cancer	0.00022	0.00491	CbGeAlD
Nilotinib—TEK—tendon—muscle cancer	0.000218	0.00485	CbGeAlD
Nilotinib—EPHA4—testis—muscle cancer	0.000215	0.0048	CbGeAlD
Nilotinib—CA3—testis—muscle cancer	0.000213	0.00474	CbGeAlD
Nilotinib—EPHB4—vagina—muscle cancer	0.000211	0.0047	CbGeAlD
Nilotinib—KIT—smooth muscle tissue—muscle cancer	0.00021	0.00468	CbGeAlD
Nilotinib—EPHB6—tendon—muscle cancer	0.000208	0.00464	CbGeAlD
Nilotinib—EPHA2—vagina—muscle cancer	0.000207	0.00462	CbGeAlD
Nilotinib—MAPK14—head—muscle cancer	0.000206	0.00458	CbGeAlD
Nilotinib—PDGFRB—smooth muscle tissue—muscle cancer	0.000205	0.00457	CbGeAlD
Nilotinib—FGR—head—muscle cancer	0.000205	0.00457	CbGeAlD
Nilotinib—MAP2K5—cardiac atrium—muscle cancer	0.000204	0.00455	CbGeAlD
Nilotinib—CA9—testis—muscle cancer	0.000204	0.00454	CbGeAlD
Nilotinib—KIT—renal system—muscle cancer	0.000202	0.0045	CbGeAlD
Nilotinib—CSF1R—cardiac atrium—muscle cancer	0.000199	0.00444	CbGeAlD
Nilotinib—MAPK14—testis—muscle cancer	0.000199	0.00443	CbGeAlD
Nilotinib—LCK—testis—muscle cancer	0.000198	0.00441	CbGeAlD
Nilotinib—FGR—testis—muscle cancer	0.000198	0.00441	CbGeAlD
Nilotinib—PDGFRB—renal system—muscle cancer	0.000197	0.0044	CbGeAlD
Nilotinib—PDGFRA—tendon—muscle cancer	0.000197	0.0044	CbGeAlD
Nilotinib—EPHB6—vagina—muscle cancer	0.000193	0.0043	CbGeAlD
Nilotinib—EPHA2—head—muscle cancer	0.000191	0.00426	CbGeAlD
Nilotinib—EPHB4—testis—muscle cancer	0.000188	0.0042	CbGeAlD
Nilotinib—TEK—head—muscle cancer	0.000187	0.00416	CbGeAlD
Nilotinib—EPHA2—testis—muscle cancer	0.000185	0.00412	CbGeAlD
Nilotinib—CA1—renal system—muscle cancer	0.000185	0.00412	CbGeAlD
Nilotinib—PDGFRA—vagina—muscle cancer	0.000183	0.00408	CbGeAlD
Nilotinib—ABL1—smooth muscle tissue—muscle cancer	0.000183	0.00407	CbGeAlD
Nilotinib—TEK—testis—muscle cancer	0.00018	0.00402	CbGeAlD
Nilotinib—EPHB6—head—muscle cancer	0.000178	0.00397	CbGeAlD
Nilotinib—MAP2K5—tendon—muscle cancer	0.000178	0.00397	CbGeAlD
Nilotinib—PDGFRB—cardiac atrium—muscle cancer	0.000177	0.00394	CbGeAlD
Nilotinib—ABL1—renal system—muscle cancer	0.000176	0.00392	CbGeAlD
Nilotinib—CSF1R—tendon—muscle cancer	0.000174	0.00387	CbGeAlD
Nilotinib—EPHB6—testis—muscle cancer	0.000172	0.00384	CbGeAlD
Nilotinib—PDGFRA—head—muscle cancer	0.000169	0.00377	CbGeAlD
Nilotinib—CSF1R—bone marrow—muscle cancer	0.000168	0.00375	CbGeAlD
Nilotinib—MAP2K5—vagina—muscle cancer	0.000165	0.00368	CbGeAlD
Nilotinib—PDGFRA—testis—muscle cancer	0.000163	0.00364	CbGeAlD
Nilotinib—CSF1R—vagina—muscle cancer	0.000161	0.00359	CbGeAlD
Nilotinib—CA2—embryo—muscle cancer	0.000158	0.00353	CbGeAlD
Nilotinib—ABL1—cardiac atrium—muscle cancer	0.000157	0.00351	CbGeAlD
Nilotinib—CA12—head—muscle cancer	0.000156	0.00348	CbGeAlD
Nilotinib—PDGFRB—tendon—muscle cancer	0.000154	0.00343	CbGeAlD
Nilotinib—KIT—bone marrow—muscle cancer	0.000153	0.0034	CbGeAlD
Nilotinib—MAP2K5—head—muscle cancer	0.000152	0.0034	CbGeAlD
Nilotinib—PDGFRB—bone marrow—muscle cancer	0.000149	0.00332	CbGeAlD
Nilotinib—CSF1R—head—muscle cancer	0.000149	0.00332	CbGeAlD
Nilotinib—MAP2K5—testis—muscle cancer	0.000147	0.00328	CbGeAlD
Nilotinib—KIT—vagina—muscle cancer	0.000146	0.00326	CbGeAlD
Nilotinib—CA4—renal system—muscle cancer	0.000144	0.00322	CbGeAlD
Nilotinib—CSF1R—testis—muscle cancer	0.000144	0.0032	CbGeAlD
Nilotinib—PDGFRB—vagina—muscle cancer	0.000143	0.00318	CbGeAlD
Nilotinib—CA1—bone marrow—muscle cancer	0.00014	0.00311	CbGeAlD
Nilotinib—ABL1—tendon—muscle cancer	0.000137	0.00306	CbGeAlD
Nilotinib—KIT—head—muscle cancer	0.000135	0.00301	CbGeAlD
Nilotinib—ABL1—bone marrow—muscle cancer	0.000133	0.00296	CbGeAlD
Nilotinib—PDGFRB—head—muscle cancer	0.000132	0.00294	CbGeAlD
Nilotinib—KIT—testis—muscle cancer	0.00013	0.00291	CbGeAlD
Nilotinib—CA4—cardiac atrium—muscle cancer	0.000129	0.00288	CbGeAlD
Nilotinib—PDGFRB—testis—muscle cancer	0.000127	0.00284	CbGeAlD
Nilotinib—ABL1—vagina—muscle cancer	0.000127	0.00284	CbGeAlD
Nilotinib—CA2—smooth muscle tissue—muscle cancer	0.000124	0.00277	CbGeAlD
Nilotinib—CA1—head—muscle cancer	0.000124	0.00276	CbGeAlD
Nilotinib—CA2—renal system—muscle cancer	0.00012	0.00267	CbGeAlD
Nilotinib—ABL1—head—muscle cancer	0.000118	0.00262	CbGeAlD
Nilotinib—CYP2C8—renal system—muscle cancer	0.000114	0.00254	CbGeAlD
Nilotinib—ABL1—testis—muscle cancer	0.000114	0.00253	CbGeAlD
Nilotinib—CA4—tendon—muscle cancer	0.000113	0.00251	CbGeAlD
Nilotinib—CA4—bone marrow—muscle cancer	0.000109	0.00243	CbGeAlD
Nilotinib—CA2—cardiac atrium—muscle cancer	0.000107	0.00239	CbGeAlD
Nilotinib—CYP2B6—renal system—muscle cancer	0.000102	0.00228	CbGeAlD
Nilotinib—CA4—head—muscle cancer	9.66e-05	0.00215	CbGeAlD
Nilotinib—CA2—tendon—muscle cancer	9.34e-05	0.00208	CbGeAlD
Nilotinib—CA4—testis—muscle cancer	9.33e-05	0.00208	CbGeAlD
Nilotinib—CA2—bone marrow—muscle cancer	9.05e-05	0.00202	CbGeAlD
Nilotinib—CA2—vagina—muscle cancer	8.67e-05	0.00193	CbGeAlD
Nilotinib—ABCG2—bone marrow—muscle cancer	8.38e-05	0.00187	CbGeAlD
Nilotinib—CYP2C8—vagina—muscle cancer	8.26e-05	0.00184	CbGeAlD
Nilotinib—ABCG2—vagina—muscle cancer	8.03e-05	0.00179	CbGeAlD
Nilotinib—CA2—head—muscle cancer	8.01e-05	0.00179	CbGeAlD
Nilotinib—CA2—testis—muscle cancer	7.74e-05	0.00172	CbGeAlD
Nilotinib—CYP3A4—renal system—muscle cancer	7.72e-05	0.00172	CbGeAlD
Nilotinib—CYP2D6—renal system—muscle cancer	7.6e-05	0.00169	CbGeAlD
Nilotinib—CYP2B6—vagina—muscle cancer	7.41e-05	0.00165	CbGeAlD
Nilotinib—CYP2C8—testis—muscle cancer	7.37e-05	0.00164	CbGeAlD
Nilotinib—ABCB1—embryo—muscle cancer	7.22e-05	0.00161	CbGeAlD
Nilotinib—ABCG2—testis—muscle cancer	7.16e-05	0.0016	CbGeAlD
Nilotinib—CYP2B6—head—muscle cancer	6.84e-05	0.00153	CbGeAlD
Nilotinib—CYP2B6—testis—muscle cancer	6.61e-05	0.00147	CbGeAlD
Nilotinib—Abdominal discomfort—Methotrexate—muscle cancer	6.2e-05	0.00126	CcSEcCtD
Nilotinib—Gastrointestinal pain—Vincristine—muscle cancer	6.2e-05	0.00126	CcSEcCtD
Nilotinib—Confusional state—Etoposide—muscle cancer	6.19e-05	0.00125	CcSEcCtD
Nilotinib—Pancytopenia—Methotrexate—muscle cancer	6.14e-05	0.00124	CcSEcCtD
Nilotinib—Infection—Etoposide—muscle cancer	6.1e-05	0.00124	CcSEcCtD
Nilotinib—Asthenia—Dactinomycin—muscle cancer	6.09e-05	0.00123	CcSEcCtD
Nilotinib—Blood creatinine increased—Doxorubicin—muscle cancer	6.07e-05	0.00123	CcSEcCtD
Nilotinib—Dysuria—Methotrexate—muscle cancer	6.05e-05	0.00123	CcSEcCtD
Nilotinib—Neutropenia—Methotrexate—muscle cancer	6.05e-05	0.00123	CcSEcCtD
Nilotinib—Dehydration—Doxorubicin—muscle cancer	6.03e-05	0.00122	CcSEcCtD
Nilotinib—Thrombocytopenia—Etoposide—muscle cancer	6.01e-05	0.00122	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Methotrexate—muscle cancer	6.01e-05	0.00122	CcSEcCtD
Nilotinib—Tachycardia—Etoposide—muscle cancer	5.99e-05	0.00121	CcSEcCtD
Nilotinib—Body temperature increased—Vincristine—muscle cancer	5.99e-05	0.00121	CcSEcCtD
Nilotinib—Abdominal pain—Vincristine—muscle cancer	5.99e-05	0.00121	CcSEcCtD
Nilotinib—Skin disorder—Etoposide—muscle cancer	5.96e-05	0.00121	CcSEcCtD
Nilotinib—Erectile dysfunction—Methotrexate—muscle cancer	5.96e-05	0.00121	CcSEcCtD
Nilotinib—Dry skin—Doxorubicin—muscle cancer	5.94e-05	0.0012	CcSEcCtD
Nilotinib—Hyperhidrosis—Etoposide—muscle cancer	5.94e-05	0.0012	CcSEcCtD
Nilotinib—Abdominal pain upper—Doxorubicin—muscle cancer	5.92e-05	0.0012	CcSEcCtD
Nilotinib—Photosensitivity reaction—Methotrexate—muscle cancer	5.9e-05	0.0012	CcSEcCtD
Nilotinib—Hypokalaemia—Doxorubicin—muscle cancer	5.9e-05	0.00119	CcSEcCtD
Nilotinib—Breast disorder—Doxorubicin—muscle cancer	5.85e-05	0.00119	CcSEcCtD
Nilotinib—Anorexia—Etoposide—muscle cancer	5.85e-05	0.00119	CcSEcCtD
Nilotinib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	5.83e-05	0.00118	CcSEcCtD
Nilotinib—Diarrhoea—Dactinomycin—muscle cancer	5.8e-05	0.00118	CcSEcCtD
Nilotinib—Pneumonia—Methotrexate—muscle cancer	5.8e-05	0.00118	CcSEcCtD
Nilotinib—Nasopharyngitis—Doxorubicin—muscle cancer	5.79e-05	0.00117	CcSEcCtD
Nilotinib—Infestation NOS—Methotrexate—muscle cancer	5.77e-05	0.00117	CcSEcCtD
Nilotinib—Infestation—Methotrexate—muscle cancer	5.77e-05	0.00117	CcSEcCtD
Nilotinib—Hypotension—Etoposide—muscle cancer	5.74e-05	0.00116	CcSEcCtD
Nilotinib—Gastritis—Doxorubicin—muscle cancer	5.73e-05	0.00116	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	5.71e-05	0.00116	CcSEcCtD
Nilotinib—Muscular weakness—Doxorubicin—muscle cancer	5.71e-05	0.00116	CcSEcCtD
Nilotinib—Renal failure—Methotrexate—muscle cancer	5.67e-05	0.00115	CcSEcCtD
Nilotinib—Abdominal distension—Doxorubicin—muscle cancer	5.64e-05	0.00114	CcSEcCtD
Nilotinib—Stomatitis—Methotrexate—muscle cancer	5.62e-05	0.00114	CcSEcCtD
Nilotinib—Conjunctivitis—Methotrexate—muscle cancer	5.6e-05	0.00114	CcSEcCtD
Nilotinib—Influenza—Doxorubicin—muscle cancer	5.6e-05	0.00113	CcSEcCtD
Nilotinib—Hypersensitivity—Vincristine—muscle cancer	5.58e-05	0.00113	CcSEcCtD
Nilotinib—Eosinophilia—Doxorubicin—muscle cancer	5.54e-05	0.00112	CcSEcCtD
Nilotinib—Paraesthesia—Etoposide—muscle cancer	5.51e-05	0.00112	CcSEcCtD
Nilotinib—Haematuria—Methotrexate—muscle cancer	5.5e-05	0.00111	CcSEcCtD
Nilotinib—Pancreatitis—Doxorubicin—muscle cancer	5.49e-05	0.00111	CcSEcCtD
Nilotinib—Dyspnoea—Etoposide—muscle cancer	5.47e-05	0.00111	CcSEcCtD
Nilotinib—ABCB1—renal system—muscle cancer	5.47e-05	0.00122	CbGeAlD
Nilotinib—Angina pectoris—Doxorubicin—muscle cancer	5.45e-05	0.00111	CcSEcCtD
Nilotinib—Hepatobiliary disease—Methotrexate—muscle cancer	5.45e-05	0.0011	CcSEcCtD
Nilotinib—Epistaxis—Methotrexate—muscle cancer	5.44e-05	0.0011	CcSEcCtD
Nilotinib—Asthenia—Vincristine—muscle cancer	5.44e-05	0.0011	CcSEcCtD
Nilotinib—Vomiting—Dactinomycin—muscle cancer	5.39e-05	0.00109	CcSEcCtD
Nilotinib—Bronchitis—Doxorubicin—muscle cancer	5.39e-05	0.00109	CcSEcCtD
Nilotinib—Rash—Dactinomycin—muscle cancer	5.35e-05	0.00108	CcSEcCtD
Nilotinib—Decreased appetite—Etoposide—muscle cancer	5.34e-05	0.00108	CcSEcCtD
Nilotinib—Pancytopenia—Doxorubicin—muscle cancer	5.32e-05	0.00108	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Etoposide—muscle cancer	5.3e-05	0.00107	CcSEcCtD
Nilotinib—Fatigue—Etoposide—muscle cancer	5.29e-05	0.00107	CcSEcCtD
Nilotinib—Constipation—Etoposide—muscle cancer	5.25e-05	0.00106	CcSEcCtD
Nilotinib—Pain—Etoposide—muscle cancer	5.25e-05	0.00106	CcSEcCtD
Nilotinib—Dysuria—Doxorubicin—muscle cancer	5.24e-05	0.00106	CcSEcCtD
Nilotinib—Neutropenia—Doxorubicin—muscle cancer	5.24e-05	0.00106	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Doxorubicin—muscle cancer	5.2e-05	0.00105	CcSEcCtD
Nilotinib—Haemoglobin—Methotrexate—muscle cancer	5.2e-05	0.00105	CcSEcCtD
Nilotinib—Diarrhoea—Vincristine—muscle cancer	5.19e-05	0.00105	CcSEcCtD
Nilotinib—Haemorrhage—Methotrexate—muscle cancer	5.18e-05	0.00105	CcSEcCtD
Nilotinib—Hepatitis—Methotrexate—muscle cancer	5.18e-05	0.00105	CcSEcCtD
Nilotinib—Pollakiuria—Doxorubicin—muscle cancer	5.17e-05	0.00105	CcSEcCtD
Nilotinib—Pharyngitis—Methotrexate—muscle cancer	5.14e-05	0.00104	CcSEcCtD
Nilotinib—Urinary tract disorder—Methotrexate—muscle cancer	5.11e-05	0.00104	CcSEcCtD
Nilotinib—Photosensitivity reaction—Doxorubicin—muscle cancer	5.11e-05	0.00104	CcSEcCtD
Nilotinib—Weight increased—Doxorubicin—muscle cancer	5.1e-05	0.00103	CcSEcCtD
Nilotinib—CYP2D6—head—muscle cancer	5.08e-05	0.00113	CbGeAlD
Nilotinib—Urethral disorder—Methotrexate—muscle cancer	5.07e-05	0.00103	CcSEcCtD
Nilotinib—Weight decreased—Doxorubicin—muscle cancer	5.07e-05	0.00103	CcSEcCtD
Nilotinib—Feeling abnormal—Etoposide—muscle cancer	5.06e-05	0.00103	CcSEcCtD
Nilotinib—Hyperglycaemia—Doxorubicin—muscle cancer	5.05e-05	0.00102	CcSEcCtD
Nilotinib—Nausea—Dactinomycin—muscle cancer	5.04e-05	0.00102	CcSEcCtD
Nilotinib—Pneumonia—Doxorubicin—muscle cancer	5.02e-05	0.00102	CcSEcCtD
Nilotinib—Gastrointestinal pain—Etoposide—muscle cancer	5.02e-05	0.00102	CcSEcCtD
Nilotinib—Dizziness—Vincristine—muscle cancer	5.01e-05	0.00102	CcSEcCtD
Nilotinib—Infestation—Doxorubicin—muscle cancer	4.99e-05	0.00101	CcSEcCtD
Nilotinib—Infestation NOS—Doxorubicin—muscle cancer	4.99e-05	0.00101	CcSEcCtD
Nilotinib—Visual impairment—Methotrexate—muscle cancer	4.99e-05	0.00101	CcSEcCtD
Nilotinib—CYP2D6—testis—muscle cancer	4.91e-05	0.0011	CbGeAlD
Nilotinib—Renal failure—Doxorubicin—muscle cancer	4.91e-05	0.000994	CcSEcCtD
Nilotinib—Erythema multiforme—Methotrexate—muscle cancer	4.89e-05	0.000992	CcSEcCtD
Nilotinib—Neuropathy peripheral—Doxorubicin—muscle cancer	4.89e-05	0.000992	CcSEcCtD
Nilotinib—Urticaria—Etoposide—muscle cancer	4.88e-05	0.000988	CcSEcCtD
Nilotinib—Jaundice—Doxorubicin—muscle cancer	4.87e-05	0.000986	CcSEcCtD
Nilotinib—Stomatitis—Doxorubicin—muscle cancer	4.87e-05	0.000986	CcSEcCtD
Nilotinib—Abdominal pain—Etoposide—muscle cancer	4.85e-05	0.000983	CcSEcCtD
Nilotinib—Body temperature increased—Etoposide—muscle cancer	4.85e-05	0.000983	CcSEcCtD
Nilotinib—Conjunctivitis—Doxorubicin—muscle cancer	4.85e-05	0.000983	CcSEcCtD
Nilotinib—Urinary tract infection—Doxorubicin—muscle cancer	4.85e-05	0.000983	CcSEcCtD
Nilotinib—Eye disorder—Methotrexate—muscle cancer	4.84e-05	0.00098	CcSEcCtD
Nilotinib—Tinnitus—Methotrexate—muscle cancer	4.83e-05	0.000978	CcSEcCtD
Nilotinib—Vomiting—Vincristine—muscle cancer	4.82e-05	0.000976	CcSEcCtD
Nilotinib—Cardiac disorder—Methotrexate—muscle cancer	4.8e-05	0.000973	CcSEcCtD
Nilotinib—Rash—Vincristine—muscle cancer	4.78e-05	0.000968	CcSEcCtD
Nilotinib—Dermatitis—Vincristine—muscle cancer	4.77e-05	0.000967	CcSEcCtD
Nilotinib—Haematuria—Doxorubicin—muscle cancer	4.76e-05	0.000965	CcSEcCtD
Nilotinib—Headache—Vincristine—muscle cancer	4.75e-05	0.000962	CcSEcCtD
Nilotinib—Hepatobiliary disease—Doxorubicin—muscle cancer	4.72e-05	0.000957	CcSEcCtD
Nilotinib—Epistaxis—Doxorubicin—muscle cancer	4.71e-05	0.000954	CcSEcCtD
Nilotinib—Angiopathy—Methotrexate—muscle cancer	4.7e-05	0.000951	CcSEcCtD
Nilotinib—Immune system disorder—Methotrexate—muscle cancer	4.68e-05	0.000947	CcSEcCtD
Nilotinib—Mediastinal disorder—Methotrexate—muscle cancer	4.67e-05	0.000945	CcSEcCtD
Nilotinib—Chills—Methotrexate—muscle cancer	4.64e-05	0.000941	CcSEcCtD
Nilotinib—Alopecia—Methotrexate—muscle cancer	4.57e-05	0.000927	CcSEcCtD
Nilotinib—Bradycardia—Doxorubicin—muscle cancer	4.56e-05	0.000924	CcSEcCtD
Nilotinib—Mental disorder—Methotrexate—muscle cancer	4.53e-05	0.000919	CcSEcCtD
Nilotinib—Hypersensitivity—Etoposide—muscle cancer	4.52e-05	0.000916	CcSEcCtD
Nilotinib—Erythema—Methotrexate—muscle cancer	4.51e-05	0.000913	CcSEcCtD
Nilotinib—Malnutrition—Methotrexate—muscle cancer	4.51e-05	0.000913	CcSEcCtD
Nilotinib—Haemoglobin—Doxorubicin—muscle cancer	4.5e-05	0.000913	CcSEcCtD
Nilotinib—Nausea—Vincristine—muscle cancer	4.5e-05	0.000912	CcSEcCtD
Nilotinib—Rhinitis—Doxorubicin—muscle cancer	4.49e-05	0.00091	CcSEcCtD
Nilotinib—Haemorrhage—Doxorubicin—muscle cancer	4.48e-05	0.000908	CcSEcCtD
Nilotinib—Hepatitis—Doxorubicin—muscle cancer	4.48e-05	0.000908	CcSEcCtD
Nilotinib—Hypoaesthesia—Doxorubicin—muscle cancer	4.46e-05	0.000904	CcSEcCtD
Nilotinib—Pharyngitis—Doxorubicin—muscle cancer	4.45e-05	0.000901	CcSEcCtD
Nilotinib—Urinary tract disorder—Doxorubicin—muscle cancer	4.43e-05	0.000897	CcSEcCtD
Nilotinib—Oedema peripheral—Doxorubicin—muscle cancer	4.42e-05	0.000895	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—muscle cancer	4.41e-05	0.000894	CcSEcCtD
Nilotinib—Asthenia—Etoposide—muscle cancer	4.41e-05	0.000892	CcSEcCtD
Nilotinib—Connective tissue disorder—Doxorubicin—muscle cancer	4.4e-05	0.000892	CcSEcCtD
Nilotinib—Urethral disorder—Doxorubicin—muscle cancer	4.39e-05	0.00089	CcSEcCtD
Nilotinib—Back pain—Methotrexate—muscle cancer	4.36e-05	0.000883	CcSEcCtD
Nilotinib—Pruritus—Etoposide—muscle cancer	4.34e-05	0.00088	CcSEcCtD
Nilotinib—Visual impairment—Doxorubicin—muscle cancer	4.32e-05	0.000875	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—muscle cancer	4.25e-05	0.00086	CcSEcCtD
Nilotinib—Erythema multiforme—Doxorubicin—muscle cancer	4.24e-05	0.000859	CcSEcCtD
Nilotinib—Diarrhoea—Etoposide—muscle cancer	4.2e-05	0.000851	CcSEcCtD
Nilotinib—Eye disorder—Doxorubicin—muscle cancer	4.19e-05	0.000849	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—muscle cancer	4.18e-05	0.000847	CcSEcCtD
Nilotinib—Tinnitus—Doxorubicin—muscle cancer	4.18e-05	0.000847	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—muscle cancer	4.16e-05	0.000844	CcSEcCtD
Nilotinib—Cardiac disorder—Doxorubicin—muscle cancer	4.16e-05	0.000843	CcSEcCtD
Nilotinib—Flushing—Doxorubicin—muscle cancer	4.16e-05	0.000843	CcSEcCtD
Nilotinib—ABCB1—bone marrow—muscle cancer	4.13e-05	0.000921	CbGeAlD
Nilotinib—Angiopathy—Doxorubicin—muscle cancer	4.07e-05	0.000824	CcSEcCtD
Nilotinib—Malaise—Methotrexate—muscle cancer	4.06e-05	0.000823	CcSEcCtD
Nilotinib—Dizziness—Etoposide—muscle cancer	4.06e-05	0.000823	CcSEcCtD
Nilotinib—Immune system disorder—Doxorubicin—muscle cancer	4.05e-05	0.00082	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—muscle cancer	4.05e-05	0.00082	CcSEcCtD
Nilotinib—Mediastinal disorder—Doxorubicin—muscle cancer	4.04e-05	0.000818	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—muscle cancer	4.03e-05	0.000817	CcSEcCtD
Nilotinib—Chills—Doxorubicin—muscle cancer	4.02e-05	0.000815	CcSEcCtD
Nilotinib—Arrhythmia—Doxorubicin—muscle cancer	4e-05	0.000811	CcSEcCtD
Nilotinib—Alopecia—Doxorubicin—muscle cancer	3.96e-05	0.000802	CcSEcCtD
Nilotinib—ABCB1—vagina—muscle cancer	3.96e-05	0.000883	CbGeAlD
Nilotinib—Cough—Methotrexate—muscle cancer	3.93e-05	0.000797	CcSEcCtD
Nilotinib—Mental disorder—Doxorubicin—muscle cancer	3.93e-05	0.000796	CcSEcCtD
Nilotinib—Vomiting—Etoposide—muscle cancer	3.9e-05	0.000791	CcSEcCtD
Nilotinib—Erythema—Doxorubicin—muscle cancer	3.9e-05	0.000791	CcSEcCtD
Nilotinib—Malnutrition—Doxorubicin—muscle cancer	3.9e-05	0.000791	CcSEcCtD
Nilotinib—Rash—Etoposide—muscle cancer	3.87e-05	0.000784	CcSEcCtD
Nilotinib—Dermatitis—Etoposide—muscle cancer	3.87e-05	0.000784	CcSEcCtD
Nilotinib—Headache—Etoposide—muscle cancer	3.85e-05	0.000779	CcSEcCtD
Nilotinib—Flatulence—Doxorubicin—muscle cancer	3.84e-05	0.000779	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—muscle cancer	3.84e-05	0.000777	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—muscle cancer	3.84e-05	0.000777	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—muscle cancer	3.84e-05	0.000777	CcSEcCtD
Nilotinib—Dysgeusia—Doxorubicin—muscle cancer	3.82e-05	0.000774	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	3.81e-05	0.000772	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—muscle cancer	3.79e-05	0.000768	CcSEcCtD
Nilotinib—Back pain—Doxorubicin—muscle cancer	3.77e-05	0.000765	CcSEcCtD
Nilotinib—Muscle spasms—Doxorubicin—muscle cancer	3.75e-05	0.00076	CcSEcCtD
Nilotinib—Confusional state—Methotrexate—muscle cancer	3.71e-05	0.000751	CcSEcCtD
Nilotinib—Vision blurred—Doxorubicin—muscle cancer	3.68e-05	0.000745	CcSEcCtD
Nilotinib—ABCB1—head—muscle cancer	3.66e-05	0.000815	CbGeAlD
Nilotinib—Infection—Methotrexate—muscle cancer	3.65e-05	0.00074	CcSEcCtD
Nilotinib—Nausea—Etoposide—muscle cancer	3.65e-05	0.000739	CcSEcCtD
Nilotinib—Ill-defined disorder—Doxorubicin—muscle cancer	3.62e-05	0.000733	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—muscle cancer	3.61e-05	0.000731	CcSEcCtD
Nilotinib—Anaemia—Doxorubicin—muscle cancer	3.61e-05	0.000731	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—muscle cancer	3.6e-05	0.00073	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—muscle cancer	3.57e-05	0.000724	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—muscle cancer	3.56e-05	0.00072	CcSEcCtD
Nilotinib—ABCB1—testis—muscle cancer	3.53e-05	0.000788	CbGeAlD
Nilotinib—Malaise—Doxorubicin—muscle cancer	3.52e-05	0.000713	CcSEcCtD
Nilotinib—Vertigo—Doxorubicin—muscle cancer	3.51e-05	0.00071	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—muscle cancer	3.51e-05	0.00071	CcSEcCtD
Nilotinib—Syncope—Doxorubicin—muscle cancer	3.5e-05	0.000709	CcSEcCtD
Nilotinib—Leukopenia—Doxorubicin—muscle cancer	3.49e-05	0.000708	CcSEcCtD
Nilotinib—Palpitations—Doxorubicin—muscle cancer	3.45e-05	0.000699	CcSEcCtD
Nilotinib—Hypotension—Methotrexate—muscle cancer	3.44e-05	0.000696	CcSEcCtD
Nilotinib—Loss of consciousness—Doxorubicin—muscle cancer	3.43e-05	0.000695	CcSEcCtD
Nilotinib—Cough—Doxorubicin—muscle cancer	3.4e-05	0.00069	CcSEcCtD
Nilotinib—Hypertension—Doxorubicin—muscle cancer	3.37e-05	0.000683	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—muscle cancer	3.35e-05	0.000679	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—muscle cancer	3.33e-05	0.000674	CcSEcCtD
Nilotinib—Chest pain—Doxorubicin—muscle cancer	3.32e-05	0.000673	CcSEcCtD
Nilotinib—Arthralgia—Doxorubicin—muscle cancer	3.32e-05	0.000673	CcSEcCtD
Nilotinib—Myalgia—Doxorubicin—muscle cancer	3.32e-05	0.000673	CcSEcCtD
Nilotinib—Anxiety—Doxorubicin—muscle cancer	3.31e-05	0.000671	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—muscle cancer	3.3e-05	0.000669	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	3.3e-05	0.000668	CcSEcCtD
Nilotinib—Discomfort—Doxorubicin—muscle cancer	3.28e-05	0.000665	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—muscle cancer	3.28e-05	0.000664	CcSEcCtD
Nilotinib—Dry mouth—Doxorubicin—muscle cancer	3.25e-05	0.000658	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—muscle cancer	3.24e-05	0.000656	CcSEcCtD
Nilotinib—Confusional state—Doxorubicin—muscle cancer	3.21e-05	0.000651	CcSEcCtD
Nilotinib—Decreased appetite—Methotrexate—muscle cancer	3.2e-05	0.000648	CcSEcCtD
Nilotinib—Oedema—Doxorubicin—muscle cancer	3.18e-05	0.000645	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—muscle cancer	3.17e-05	0.000643	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—muscle cancer	3.17e-05	0.000642	CcSEcCtD
Nilotinib—Infection—Doxorubicin—muscle cancer	3.16e-05	0.000641	CcSEcCtD
Nilotinib—Pain—Methotrexate—muscle cancer	3.14e-05	0.000637	CcSEcCtD
Nilotinib—Shock—Doxorubicin—muscle cancer	3.13e-05	0.000635	CcSEcCtD
Nilotinib—Nervous system disorder—Doxorubicin—muscle cancer	3.12e-05	0.000633	CcSEcCtD
Nilotinib—Thrombocytopenia—Doxorubicin—muscle cancer	3.12e-05	0.000632	CcSEcCtD
Nilotinib—Tachycardia—Doxorubicin—muscle cancer	3.11e-05	0.00063	CcSEcCtD
Nilotinib—Skin disorder—Doxorubicin—muscle cancer	3.09e-05	0.000627	CcSEcCtD
Nilotinib—Hyperhidrosis—Doxorubicin—muscle cancer	3.08e-05	0.000624	CcSEcCtD
Nilotinib—Anorexia—Doxorubicin—muscle cancer	3.04e-05	0.000615	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—muscle cancer	3.03e-05	0.000614	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—muscle cancer	3.01e-05	0.000609	CcSEcCtD
Nilotinib—Hypotension—Doxorubicin—muscle cancer	2.98e-05	0.000603	CcSEcCtD
Nilotinib—Urticaria—Methotrexate—muscle cancer	2.92e-05	0.000592	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—muscle cancer	2.91e-05	0.000589	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—muscle cancer	2.91e-05	0.000589	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	2.9e-05	0.000588	CcSEcCtD
Nilotinib—Insomnia—Doxorubicin—muscle cancer	2.88e-05	0.000584	CcSEcCtD
Nilotinib—Paraesthesia—Doxorubicin—muscle cancer	2.86e-05	0.000579	CcSEcCtD
Nilotinib—Dyspnoea—Doxorubicin—muscle cancer	2.84e-05	0.000575	CcSEcCtD
Nilotinib—Dyspepsia—Doxorubicin—muscle cancer	2.8e-05	0.000568	CcSEcCtD
Nilotinib—Decreased appetite—Doxorubicin—muscle cancer	2.77e-05	0.000561	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Doxorubicin—muscle cancer	2.75e-05	0.000557	CcSEcCtD
Nilotinib—Fatigue—Doxorubicin—muscle cancer	2.75e-05	0.000556	CcSEcCtD
Nilotinib—Pain—Doxorubicin—muscle cancer	2.72e-05	0.000552	CcSEcCtD
Nilotinib—Constipation—Doxorubicin—muscle cancer	2.72e-05	0.000552	CcSEcCtD
Nilotinib—Hypersensitivity—Methotrexate—muscle cancer	2.71e-05	0.000549	CcSEcCtD
Nilotinib—Asthenia—Methotrexate—muscle cancer	2.64e-05	0.000535	CcSEcCtD
Nilotinib—Feeling abnormal—Doxorubicin—muscle cancer	2.62e-05	0.000532	CcSEcCtD
Nilotinib—Gastrointestinal pain—Doxorubicin—muscle cancer	2.6e-05	0.000528	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—muscle cancer	2.6e-05	0.000527	CcSEcCtD
Nilotinib—Urticaria—Doxorubicin—muscle cancer	2.53e-05	0.000513	CcSEcCtD
Nilotinib—Body temperature increased—Doxorubicin—muscle cancer	2.52e-05	0.00051	CcSEcCtD
Nilotinib—Abdominal pain—Doxorubicin—muscle cancer	2.52e-05	0.00051	CcSEcCtD
Nilotinib—Diarrhoea—Methotrexate—muscle cancer	2.52e-05	0.00051	CcSEcCtD
Nilotinib—Dizziness—Methotrexate—muscle cancer	2.43e-05	0.000493	CcSEcCtD
Nilotinib—Hypersensitivity—Doxorubicin—muscle cancer	2.35e-05	0.000475	CcSEcCtD
Nilotinib—Vomiting—Methotrexate—muscle cancer	2.34e-05	0.000474	CcSEcCtD
Nilotinib—Rash—Methotrexate—muscle cancer	2.32e-05	0.00047	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—muscle cancer	2.32e-05	0.000469	CcSEcCtD
Nilotinib—Headache—Methotrexate—muscle cancer	2.3e-05	0.000467	CcSEcCtD
Nilotinib—Asthenia—Doxorubicin—muscle cancer	2.28e-05	0.000463	CcSEcCtD
Nilotinib—Pruritus—Doxorubicin—muscle cancer	2.25e-05	0.000456	CcSEcCtD
Nilotinib—Nausea—Methotrexate—muscle cancer	2.18e-05	0.000443	CcSEcCtD
Nilotinib—Diarrhoea—Doxorubicin—muscle cancer	2.18e-05	0.000441	CcSEcCtD
Nilotinib—Dizziness—Doxorubicin—muscle cancer	2.11e-05	0.000427	CcSEcCtD
Nilotinib—Vomiting—Doxorubicin—muscle cancer	2.02e-05	0.00041	CcSEcCtD
Nilotinib—Rash—Doxorubicin—muscle cancer	2.01e-05	0.000407	CcSEcCtD
Nilotinib—Dermatitis—Doxorubicin—muscle cancer	2.01e-05	0.000406	CcSEcCtD
Nilotinib—Headache—Doxorubicin—muscle cancer	1.99e-05	0.000404	CcSEcCtD
Nilotinib—Nausea—Doxorubicin—muscle cancer	1.89e-05	0.000383	CcSEcCtD
Nilotinib—PDGFRB—Disease—ENO2—muscle cancer	1.01e-05	0.000152	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1e-05	0.000152	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—FOXO4—muscle cancer	9.88e-06	0.000149	CbGpPWpGaD
Nilotinib—MAPK14—MAPK Signaling Pathway—TP53—muscle cancer	9.68e-06	0.000146	CbGpPWpGaD
Nilotinib—KIT—Disease—FOXO4—muscle cancer	9.64e-06	0.000146	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—KIT—muscle cancer	9.55e-06	0.000144	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—MDM2—muscle cancer	9.53e-06	0.000144	CbGpPWpGaD
Nilotinib—MAPK11—Cellular responses to stress—TP53—muscle cancer	9.45e-06	0.000143	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—FOXO4—muscle cancer	9.4e-06	0.000142	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—FH—muscle cancer	9.34e-06	0.000141	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—VEGFA—muscle cancer	9.3e-06	0.00014	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CNR1—muscle cancer	9.22e-06	0.000139	CbGpPWpGaD
Nilotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	9.18e-06	0.000139	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—KIT—muscle cancer	9.17e-06	0.000139	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HMGA1—muscle cancer	9.17e-06	0.000138	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—FOXO4—muscle cancer	9.13e-06	0.000138	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—FOXO1—muscle cancer	9.06e-06	0.000137	CbGpPWpGaD
Nilotinib—HCK—Immune System—KIT—muscle cancer	9.03e-06	0.000136	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—FOXO4—muscle cancer	8.93e-06	0.000135	CbGpPWpGaD
Nilotinib—MAPK14—Cellular responses to stress—VEGFA—muscle cancer	8.93e-06	0.000135	CbGpPWpGaD
Nilotinib—MAPK14—Cellular Senescence—TP53—muscle cancer	8.93e-06	0.000135	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—FOXO4—muscle cancer	8.9e-06	0.000135	CbGpPWpGaD
Nilotinib—LCK—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	8.9e-06	0.000134	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—MDM2—muscle cancer	8.81e-06	0.000133	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CNR1—muscle cancer	8.77e-06	0.000132	CbGpPWpGaD
Nilotinib—MAPK14—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	8.74e-06	0.000132	CbGpPWpGaD
Nilotinib—LYN—Immune System—FOXO4—muscle cancer	8.72e-06	0.000132	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PTCH1—muscle cancer	8.71e-06	0.000132	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—FOXO1—muscle cancer	8.7e-06	0.000131	CbGpPWpGaD
Nilotinib—ABL1—Immune System—FOXO4—muscle cancer	8.68e-06	0.000131	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PTCH1—muscle cancer	8.63e-06	0.00013	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—KIT—muscle cancer	8.6e-06	0.00013	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—FOXO1—muscle cancer	8.55e-06	0.000129	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—MED12—muscle cancer	8.49e-06	0.000128	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—KIT—muscle cancer	8.42e-06	0.000127	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—KIT—muscle cancer	8.38e-06	0.000127	CbGpPWpGaD
Nilotinib—HCK—Disease—KIT—muscle cancer	8.33e-06	0.000126	CbGpPWpGaD
Nilotinib—CA14—Metabolism—PTGS2—muscle cancer	8.33e-06	0.000126	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—FOXO4—muscle cancer	8.26e-06	0.000125	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—KIT—muscle cancer	8.26e-06	0.000125	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—FOXO4—muscle cancer	8.22e-06	0.000124	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—KIT—muscle cancer	8.18e-06	0.000124	CbGpPWpGaD
Nilotinib—BLK—Immune System—KIT—muscle cancer	8.18e-06	0.000124	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	8.17e-06	0.000123	CbGpPWpGaD
Nilotinib—FGR—Immune System—KIT—muscle cancer	8.15e-06	0.000123	CbGpPWpGaD
Nilotinib—CA6—Metabolism—PTGS2—muscle cancer	8.12e-06	0.000123	CbGpPWpGaD
Nilotinib—LCK—Disease—ENO2—muscle cancer	8.09e-06	0.000122	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—KIT—muscle cancer	8.09e-06	0.000122	CbGpPWpGaD
Nilotinib—LYN—Axon guidance—VEGFA—muscle cancer	7.99e-06	0.000121	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—KIT—muscle cancer	7.99e-06	0.000121	CbGpPWpGaD
Nilotinib—ABL1—Axon guidance—VEGFA—muscle cancer	7.96e-06	0.00012	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—MDM2—muscle cancer	7.95e-06	0.00012	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—FH—muscle cancer	7.91e-06	0.000119	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PTCH1—muscle cancer	7.85e-06	0.000119	CbGpPWpGaD
Nilotinib—BRAF—Disease—FOXO1—muscle cancer	7.82e-06	0.000118	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ENO2—muscle cancer	7.74e-06	0.000117	CbGpPWpGaD
Nilotinib—KIT—Immune System—FOXO1—muscle cancer	7.71e-06	0.000116	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—MDM2—muscle cancer	7.63e-06	0.000115	CbGpPWpGaD
Nilotinib—CA7—Metabolism—PTGS2—muscle cancer	7.58e-06	0.000115	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—VEGFA—muscle cancer	7.58e-06	0.000114	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IGF2—muscle cancer	7.54e-06	0.000114	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—MDM2—muscle cancer	7.52e-06	0.000114	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FOXO4—muscle cancer	7.49e-06	0.000113	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PTCH1—muscle cancer	7.43e-06	0.000112	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FOXO4—muscle cancer	7.42e-06	0.000112	CbGpPWpGaD
Nilotinib—LCK—Disease—HMGA1—muscle cancer	7.36e-06	0.000111	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CNR1—muscle cancer	7.35e-06	0.000111	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—FOXO1—muscle cancer	7.3e-06	0.00011	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CNR1—muscle cancer	7.28e-06	0.00011	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—MDM2—muscle cancer	7.22e-06	0.000109	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—MED12—muscle cancer	7.2e-06	0.000109	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IGF2—muscle cancer	7.17e-06	0.000108	CbGpPWpGaD
Nilotinib—LCK—Immune System—FOXO4—muscle cancer	7.15e-06	0.000108	CbGpPWpGaD
Nilotinib—KIT—Disease—FOXO1—muscle cancer	7.12e-06	0.000108	CbGpPWpGaD
Nilotinib—HCK—Immune System—MDM2—muscle cancer	7.11e-06	0.000107	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—TP53—muscle cancer	7.02e-06	0.000106	CbGpPWpGaD
Nilotinib—CA12—Metabolism—PTGS2—muscle cancer	7.02e-06	0.000106	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—FOXO1—muscle cancer	6.94e-06	0.000105	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—KIT—muscle cancer	6.9e-06	0.000104	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	6.9e-06	0.000104	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—FH—muscle cancer	6.89e-06	0.000104	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—MDM2—muscle cancer	6.78e-06	0.000102	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FOXO4—muscle cancer	6.75e-06	0.000102	CbGpPWpGaD
Nilotinib—MAPK14—Cellular responses to stress—TP53—muscle cancer	6.75e-06	0.000102	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—FOXO1—muscle cancer	6.74e-06	0.000102	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTCH1—muscle cancer	6.7e-06	0.000101	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	6.65e-06	0.0001	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—MDM2—muscle cancer	6.63e-06	0.0001	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—KIT—muscle cancer	6.63e-06	0.0001	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CNR1—muscle cancer	6.63e-06	0.0001	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—MDM2—muscle cancer	6.6e-06	9.98e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—FOXO1—muscle cancer	6.6e-06	9.97e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—FOXO4—muscle cancer	6.6e-06	9.97e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—FOXO1—muscle cancer	6.58e-06	9.94e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ENO2—muscle cancer	6.57e-06	9.92e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—MDM2—muscle cancer	6.56e-06	9.92e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTCH1—muscle cancer	6.56e-06	9.9e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—KIT—muscle cancer	6.52e-06	9.84e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—MDM2—muscle cancer	6.51e-06	9.83e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—FH—muscle cancer	6.49e-06	9.81e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—MDM2—muscle cancer	6.44e-06	9.73e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—MDM2—muscle cancer	6.44e-06	9.73e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—FOXO1—muscle cancer	6.44e-06	9.73e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—FH—muscle cancer	6.44e-06	9.73e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—MDM2—muscle cancer	6.42e-06	9.7e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—FOXO1—muscle cancer	6.41e-06	9.68e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FOXO4—muscle cancer	6.39e-06	9.65e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—MDM2—muscle cancer	6.37e-06	9.62e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—PTGS2—muscle cancer	6.33e-06	9.56e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—MDM2—muscle cancer	6.29e-06	9.5e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CNR1—muscle cancer	6.27e-06	9.48e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTCH1—muscle cancer	6.21e-06	9.39e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—FOXO1—muscle cancer	6.1e-06	9.22e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—FOXO1—muscle cancer	6.07e-06	9.17e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IGF2—muscle cancer	6.01e-06	9.08e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—KIT—muscle cancer	5.96e-06	9e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IGF2—muscle cancer	5.95e-06	8.99e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FOXO4—muscle cancer	5.76e-06	8.7e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—VEGFA—muscle cancer	5.7e-06	8.62e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—VEGFA—muscle cancer	5.68e-06	8.58e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CNR1—muscle cancer	5.65e-06	8.54e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FOXO4—muscle cancer	5.64e-06	8.52e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—PTGS2—muscle cancer	5.6e-06	8.46e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—VEGFA—muscle cancer	5.6e-06	8.45e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—VEGFA—muscle cancer	5.57e-06	8.41e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—KIT—muscle cancer	5.56e-06	8.4e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CNR1—muscle cancer	5.53e-06	8.36e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FOXO1—muscle cancer	5.53e-06	8.35e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FOXO1—muscle cancer	5.48e-06	8.28e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—MDM2—muscle cancer	5.44e-06	8.21e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IGF2—muscle cancer	5.42e-06	8.18e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—VEGFA—muscle cancer	5.41e-06	8.17e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTCH1—muscle cancer	5.37e-06	8.12e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—PTGS2—muscle cancer	5.37e-06	8.11e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FOXO4—muscle cancer	5.34e-06	8.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—VEGFA—muscle cancer	5.3e-06	8.01e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—KIT—muscle cancer	5.29e-06	7.99e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—MED12—muscle cancer	5.28e-06	7.98e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—FOXO1—muscle cancer	5.28e-06	7.97e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CNR1—muscle cancer	5.25e-06	7.92e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	5.24e-06	7.91e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—MDM2—muscle cancer	5.22e-06	7.89e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—PTGS2—muscle cancer	5.15e-06	7.78e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—KIT—muscle cancer	5.14e-06	7.76e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—MDM2—muscle cancer	5.13e-06	7.75e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IGF2—muscle cancer	5.13e-06	7.75e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—KIT—muscle cancer	5.03e-06	7.6e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—KIT—muscle cancer	5.01e-06	7.57e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FOXO1—muscle cancer	4.99e-06	7.53e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—KIT—muscle cancer	4.91e-06	7.41e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—KIT—muscle cancer	4.88e-06	7.38e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—FOXO1—muscle cancer	4.87e-06	7.36e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ENO2—muscle cancer	4.81e-06	7.27e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FOXO1—muscle cancer	4.72e-06	7.13e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—MDM2—muscle cancer	4.69e-06	7.09e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KIT—muscle cancer	4.65e-06	7.03e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—MDM2—muscle cancer	4.63e-06	6.99e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KIT—muscle cancer	4.63e-06	6.99e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IGF2—muscle cancer	4.62e-06	6.98e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FOXO4—muscle cancer	4.62e-06	6.98e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—VEGFA—muscle cancer	4.59e-06	6.93e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CNR1—muscle cancer	4.54e-06	6.85e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—PTGS2—muscle cancer	4.53e-06	6.84e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—PTGS2—muscle cancer	4.53e-06	6.84e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IGF2—muscle cancer	4.52e-06	6.83e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MED12—muscle cancer	4.47e-06	6.75e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—MDM2—muscle cancer	4.38e-06	6.62e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IGF2—muscle cancer	4.29e-06	6.48e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—MDM2—muscle cancer	4.27e-06	6.45e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FOXO1—muscle cancer	4.25e-06	6.42e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—FH—muscle cancer	4.25e-06	6.41e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—muscle cancer	4.23e-06	6.39e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KIT—muscle cancer	4.21e-06	6.36e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—muscle cancer	4.21e-06	6.36e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KIT—muscle cancer	4.17e-06	6.31e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MDM2—muscle cancer	4.16e-06	6.29e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FOXO1—muscle cancer	4.16e-06	6.29e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—PTGS2—muscle cancer	4.12e-06	6.22e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ENO2—muscle cancer	4.08e-06	6.16e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MDM2—muscle cancer	4.04e-06	6.11e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—KIT—muscle cancer	4.02e-06	6.08e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—muscle cancer	4.01e-06	6.05e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MDM2—muscle cancer	3.96e-06	5.98e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	3.96e-06	5.98e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—MDM2—muscle cancer	3.95e-06	5.96e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FOXO1—muscle cancer	3.95e-06	5.96e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PTGS2—muscle cancer	3.9e-06	5.89e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MED12—muscle cancer	3.89e-06	5.88e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—MDM2—muscle cancer	3.86e-06	5.84e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—MDM2—muscle cancer	3.85e-06	5.81e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—KIT—muscle cancer	3.71e-06	5.61e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF2—muscle cancer	3.71e-06	5.6e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MED12—muscle cancer	3.67e-06	5.54e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—MDM2—muscle cancer	3.66e-06	5.53e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MDM2—muscle cancer	3.64e-06	5.5e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MED12—muscle cancer	3.64e-06	5.5e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KIT—muscle cancer	3.6e-06	5.43e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ENO2—muscle cancer	3.55e-06	5.36e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PTGS2—muscle cancer	3.51e-06	5.31e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—muscle cancer	3.47e-06	5.24e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FOXO1—muscle cancer	3.41e-06	5.15e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ENO2—muscle cancer	3.35e-06	5.05e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MDM2—muscle cancer	3.32e-06	5.01e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ENO2—muscle cancer	3.32e-06	5.01e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MDM2—muscle cancer	3.29e-06	4.97e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KIT—muscle cancer	3.24e-06	4.89e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.19e-06	4.81e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KIT—muscle cancer	3.17e-06	4.79e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—MDM2—muscle cancer	3.17e-06	4.78e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—VEGFA—muscle cancer	3.16e-06	4.78e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KIT—muscle cancer	3.01e-06	4.54e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—VEGFA—muscle cancer	3.01e-06	4.54e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MDM2—muscle cancer	2.99e-06	4.52e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MDM2—muscle cancer	2.92e-06	4.42e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MDM2—muscle cancer	2.83e-06	4.28e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—muscle cancer	2.82e-06	4.26e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—muscle cancer	2.7e-06	4.07e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KIT—muscle cancer	2.6e-06	3.93e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.59e-06	3.92e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MDM2—muscle cancer	2.55e-06	3.85e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—muscle cancer	2.52e-06	3.81e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MDM2—muscle cancer	2.5e-06	3.77e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—muscle cancer	2.5e-06	3.77e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MED12—muscle cancer	2.4e-06	3.62e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—muscle cancer	2.39e-06	3.61e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MDM2—muscle cancer	2.37e-06	3.58e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—muscle cancer	2.29e-06	3.45e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—muscle cancer	2.27e-06	3.43e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—muscle cancer	2.27e-06	3.43e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ENO2—muscle cancer	2.19e-06	3.3e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—muscle cancer	2.15e-06	3.25e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MDM2—muscle cancer	2.05e-06	3.09e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—muscle cancer	1.94e-06	2.93e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—muscle cancer	1.9e-06	2.88e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—muscle cancer	1.9e-06	2.87e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—muscle cancer	1.89e-06	2.85e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—muscle cancer	1.8e-06	2.72e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—muscle cancer	1.72e-06	2.59e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—muscle cancer	1.68e-06	2.53e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—muscle cancer	1.63e-06	2.45e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—muscle cancer	1.55e-06	2.35e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—muscle cancer	1.46e-06	2.21e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—muscle cancer	1.43e-06	2.17e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—muscle cancer	1.42e-06	2.14e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—muscle cancer	1.36e-06	2.05e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—muscle cancer	1.24e-06	1.87e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—muscle cancer	1.17e-06	1.77e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—muscle cancer	1.17e-06	1.76e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—muscle cancer	1.16e-06	1.74e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—muscle cancer	7.62e-07	1.15e-05	CbGpPWpGaD
